Darden Restaurants vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orlando full-service restaurant operator (NYSE: DRI) ~$12.1B FY2025 revenue; Olive Garden 900+ locations, Ruth's Chris acquisition 2023, LongHorn expansion, competing with Bloomin' Brands and Texas Roadhouse.
About
Darden Restaurants, Inc. is an Orlando, Florida-based full-service restaurant operator — publicly traded on the New York Stock Exchange (NYSE: DRI) as an S&P 500 Consumer Discretionary component — owning and operating approximately 2,000 restaurants across eight brands including Olive Garden (Italian casual dining — 900+ locations), LongHorn Steakhouse (casual steakhouse — 600+ locations), The Capital Grille (upscale steakhouse — 60+ locations), Yard House (upscale casual — 80+ locations), Cheddar's Scratch Kitchen (value casual dining), Bahama Breeze, Seasons 52, and Eddie V's through approximately 175,000 employees. In fiscal year 2025 (ending May 2025), Darden reported revenues of approximately $12.1 billion, integrating Ruth's Chris Steak House (acquired for $715 million in 2023, adding 150+ fine dining steakhouse locations) and navigating a casual dining environment where value-seeking consumer behavior and competitive pressure from fast-casual alternatives (Chipotle, Chick-fil-A) challenged traffic counts at all casual dining brands. CEO Rick Cardenas has executed "Back to Basics" operational simplification — reducing menu item counts at Olive Garden (eliminating Never Ending Pasta Bowl in 2024, the decades-long promotional fixture), standardizing kitchen operations across the company, and investing in employee wages and training to improve service quality and reduce turnover. Olive Garden's "Never Ending Breadsticks and Salad" hospitality model and its brand loyalty (highest unaided awareness of any full-service Italian restaurant in the US) provide Darden a durable casual dining anchor that generates reliable traffic from family celebrations, date nights, and business casual dining occasions.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.